Piper Jaffray Companies Raises Catalyst Pharmaceuticals (CPRX) Price Target to $7.50

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its target price upped by Piper Jaffray Companies from $5.00 to $7.50 in a research report report published on Thursday. They currently have an overweight rating on the biopharmaceutical company’s stock. Piper Jaffray Companies also issued estimates for Catalyst Pharmaceuticals’ FY2022 earnings at $1.11 EPS.

A number of other research firms have also issued reports on CPRX. BidaskClub raised shares of Catalyst Pharmaceuticals from a strong sell rating to a sell rating in a research note on Thursday, September 27th. Cantor Fitzgerald set a $8.00 target price on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, October 3rd. Oppenheimer set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, October 16th. Finally, Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, October 10th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $6.35.

Catalyst Pharmaceuticals stock opened at $2.34 on Thursday. Catalyst Pharmaceuticals has a 52-week low of $2.18 and a 52-week high of $4.18.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). As a group, research analysts forecast that Catalyst Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

In related news, Director Charles B. O’keeffe purchased 20,000 shares of the company’s stock in a transaction on Friday, December 14th. The shares were bought at an average cost of $2.50 per share, for a total transaction of $50,000.00. Following the transaction, the director now owns 543,376 shares of the company’s stock, valued at $1,358,440. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 9.30% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $157,000. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Catalyst Pharmaceuticals by 152.9% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 42,900 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 25,940 shares in the last quarter. Lido Advisors LLC raised its position in shares of Catalyst Pharmaceuticals by 46.5% during the 2nd quarter. Lido Advisors LLC now owns 87,506 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 27,766 shares in the last quarter. Rhumbline Advisers raised its position in shares of Catalyst Pharmaceuticals by 34.7% during the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 23,383 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Catalyst Pharmaceuticals by 12.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 208,404 shares of the biopharmaceutical company’s stock worth $651,000 after buying an additional 23,500 shares in the last quarter. Institutional investors own 49.61% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Featured Article: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply